Vanguard Global Advisers
IRMD icon

Vanguard Global Advisers’s iRadimed IRMD Stock Holding History

Vanguard Global Advisers’s Portfolio IRMD Stock Details IRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$308K Sell
3,225
-706
-18% -$64.3K ﹤0.01% 2318
2026
Q1 		$378K Buy
+3,931
New +$393K ﹤0.01% 2161

Other funds holding IRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Copeland Capital Management Conshohocken, Pennsylvania $4.87B AUM 31.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's IRMD Position: Q2 2026 in Review

Vanguard Global Advisers reduced its iRadimed (IRMD) stake by 18% in Q2 2026, selling an estimated $64.3K and leaving 3,225 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #2318.

Vanguard Global Advisers first reported a position in IRMD in Q1 2026 and has held it in 2 quarters since. The position peaked at $378K in Q1 2026. 211 funds tracked by Wall St. Rank hold IRMD as of Q2 2026.

  • Vanguard Global Advisers held 3,225 shares of iRadimed worth $308K as of Q2 2026.
  • Vanguard Global Advisers sold 706 iRadimed shares in Q2 2026, an estimated $64.3K.
  • iRadimed made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #2318 holding.
  • Vanguard Global Advisers first reported a position in iRadimed in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Global Advisers's iRadimed position peaked at $378K in Q1 2026.
  • 211 funds tracked by Wall St. Rank held iRadimed as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.